NICE TA554 - relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years. (Decision date - Feb 2019)
DNP:
NICE TA842 - treating follicular lymphoma after 2 or more therapies. Terminated
appraisal. (Decision date - December 2022)
NICE TA933 Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies. Terminated appraisal, replaces NICE TA567 (Decision - December 2023)
Red Drug Classifications
1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
8. NHS England commissioned – to be used in line with NHSE commissioning intentions